Epidemiological, Clinical characteristics and Drug resistance situation of Culture-confirmed Children TBM in Southwest of China: A 6-Year Retrospective Study

Dong-Mei Wang
   Public health clinical centers of chengdu  https://orcid.org/0000-0003-0280-8049

Qing-Feng Li
   PHCCC

Ma Zhu
   PHCCC

Gui-Hui Wu
   PHCCC

Xi Li
   PHCCC

Yuan-Hong Xu
   PHCCC

Jing Zhong
   PHCCC

Jia Luo
   PHCCC

Ying-Jie Li
   PHCCC

Bin-Wu Ying
   Department of Laboratory Medicine, West China Hospital, Sichuan University

Chuan-Min Tao (✉ taochuanmin123@163.com)
   Department of Laboratory Medicine, West China Hospital, Sichuan University

Research article

Keywords: Epidemiology, Clinical features, Drug resistance, Tuberculosis, Meningeal, Child

Posted Date: February 18th, 2020

DOI: https://doi.org/10.21203/rs.2.9479/v5
Abstract

Background: Sichuan is a province located in southwestern China, which have a higher incidence of tuberculosis (TB). This study aimed to analyze the epidemiological and clinical characteristics, as well as drug resistance in culture-confirmed children with Tuberculosis meningitis (TBM) in Southwest of China.

Materials and Methods: We performed a retrospective study on children (<14 years old) with cerebrospinal fluid (CSF) culture-confirmed TBM between January 2013 and December 2018 at Public Health Clinical Center of Chengdu (PHCCC). Mycobacterium tuberculosis (MTB) drug sensitivity testing (DST) was performed using the MicroDST TM method. The age, gender, family history of tuberculosis, status of Bacillus Calmette–Guérin (BCG) vaccination, residential areas information, clinical, laboratory, and radiological features were recorded. Data were analyzed using SPSS Statistics Client 25.0, and the change in drug resistance rate was examined using the Kruskal-Wallis test.

Results: Among 319 patients clinically diagnosed with TBM, 42 cases were Mycobacterial culture-positive, with a positive rate of 13.2 per 100 patients. Their median age was nine years, and the distribution was equal among female and male patients. Among 42 patients who were enrolled in the study, 1/42 (2.38%) passed away. Children with TBM were concentrated in the minority areas of western Sichuan, where 34/42 (81.0%) patients with TBM were ethnic minorities, and only 2/42 (4.76%) received BCG vaccination in the past. Chest X-rays changes were observed in all patients. Fever and headache were the most common presenting symptom. Thirty-five (83.3%) patients suffered from neck stiffness, and 30/42 (71.4%) had high CSF pressure. DST results showed that the resistance rate was high; resistance to any anti-tuberculosis drug (ATD) was observed in 13 (31.0%) patient isolates, while multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) were found in 2 (4.8%) and 1 (2.4%) patients, respectively.

Conclusions: TBM among children in Southwest China was mainly concentrated in the minority areas of western Sichuan. The most common symptoms were fever, headache, and neck stiffness and all patients had positive chest X-ray findings. In addition, high rates of drug resistance were found; and more than 95% of patients did not receive BCG vaccination at birth.

Background

According to the latest statistics, there were estimated 1.2 million Tuberculosis (TB) deaths among HIV-negative people in 2018. Among those, 14% were in children younger than 15 years [1]. TBM with the case fatality rate of 30% is among the most severe types of extra-pulmonary tuberculosis. In our previous studies, we have found that TBM accounts for about 8.1% of all culture-confirmed TB cases [2]. Meanwhile, children's tuberculosis morbidity and mortality have the highest rates among the infectious diseases in China, with severe tuberculosis, TBM and multiple drug-resistant TB being on the rise.

Sichuan is a Chinese province located in the southwest of China. This area is also known as Minority Enclaves. Because of the remote geographical position and control paucity of local medical services, this
area has very high incidence of TB. Consequently, identifying the epidemiological and clinical characteristics, drug resistance and the geographical distribution of children with TBM can provide a scientific basis for the prevention, control, diagnosis, and treatment of the disease.

**Methods**

**Ethics approval and Informed consent**

This study was approved by the Ethics Committee of PHCCC on [2017Y] 025. As this was a retrospective study and all patient information used in this study were routinely collected through mandatory notification system, the ethics committee waived the requirement for informed consent.

**Study Population**

Sichuan province lies in the southwest of China and is one of China’s largest provinces. Our study was carried out at the PHCCC. This institution is the authorized hospital for treating TB in Southwest China (population around 89 million).

This retrospective study enrolled consecutive CSF culture-positive Mycobacterium tuberculosis cases that were confirmed and treated at the PHCCC between January 2013 and December 2018. TBM was diagnosed based on the Chinese Pulmonary Tuberculosis Diagnostic Criteria (WS 288–2017), the Chinese’ TB volume of clinical diagnosis and treatment guidelines’ (Chinese Medical Association, 2005), and the updated World Health Organization (WHO) guidelines [3]. A total of 319 potential children patients with TBM were recruited, 42 (13.2%) were Mycobacterial culture positive. The medical records of all 42 patients with culture-confirmed TBM were reviewed; data was collected on demographics, clinical, radiological and laboratory findings at presentation and outcome, including ATD toxicity. ATD induced hepatotoxicity was defined as serum alanine aminotransferase (ALT) ≥ 3 times the upper limit of normal (ULN). BCG vaccination status was determined by self-report and forearm scar examination.

**Bacterial strains culture, identification and drug sensitivity**

BACTEC MGIT 960 system (Becton Dickinson & Co., NJ, USA) was used for Mycobacteria culturing. Clinical sterile CSF samples were collected, low volume CSF samples (< 0.5ml) were directly inoculated into BACTEC MGIT 960 culture tubes. Where the CSF volume was > 0.5ml, the upper membrane and lower 0.5ml, including precipitates, were inoculated into the BACTEC MGIT 960 culture tube. WHO recommended neutralization, and the centrifugation method was used for the purulent or bloody CSF specimens. DST of the culture-positive MTB isolates was performed using MicroDST™ (Yinke AUTOBIO diagnostics Co., Ltd., Zhuhai, China) following the manufacturer’s instructions. The following first and second-line drugs were applied: isoniazid (INH, 0.4 μg/mL and 1.6 μg/mL), rifampicin (RIF, 2.0 μg/mL and 8.0 μg/mL), streptomycin (STR, 2.0 μg/mL and 8.0 μg/mL) and ethambutol (EMB, 5.0 μg/mL and 20.0 μg/mL); fluoroquinolone drugs ofloxacin (OFX, 1.5 μg/mL and 2.0 μg/mL), levofloxacin (LFX, 2.0 μg/mL and 8.0 μg/mL), and moxifloxacin (MFX, 0.5 μg/mL and 2.0 μg/mL). In addition, oral bacteriostatic
second-line ATDs (prothionamide (PTO, 10.0 μg/mL and 40.0 μg/mL), rifabutin (RFB, 0.75 μg/mL and 3 μg/mL); and the second line parenteral agents (injectable ATDs) amikacin (AMK, 1.0 μg/mL and 4 μg/mL) and capreomycin (CM, 2.5 μg/mL and 10 μg/mL) were used. The control strain H37Rv was monitored. P-nitrobenzoic acid (PNB) and thiophene-2-carboxylic acid hydrazide (TCH) were first used for MTB identification, while TB-DNA (CapitalBio Corporation) was also used for further identification of species/complex levels.

**Laboratory Quality Control**

External quality assessment (EQA) was conducted at the National Tuberculosis Reference Laboratory of the Chinese Center for Disease Control and Prevention. EQA included smear, culture, and DST. Blinded retesting of a random selection of ≈10% of isolates from the study laboratory was conducted in a superior laboratory.

**Statistical analysis**

Data were analyzed using SPSS Statistics Client 19.0 (SPSS Inc., IL, USA). The measurement data of normal distribution were expressed as median or mean ± standard deviation, and categorical variables were expressed as the number and percentage. The Cruskal-Wallis analysis was used to analyze the drug resistance rate of ATD strains of MTB within 6 years; the level of significance was set at $P < 0.05$.

**Results**

**Demographic and clinical characteristics**

The median age of 42 children with TBM was nine years, ranging from 5 months to 14 years. Twenty-nine patients (69.0%) were between ages 5 to 14 years. The male: female ratio was 1:1. Thirty-four (81.0%) children belonged to ethnic minorities (Tibetan, Yi and Qiang), and none of the patients in this group received a BCG vaccination or had a BCG vaccination mark on the forearm. Only 2/42 (4.76%) of the patients who received BCG vaccination were Han Chinese from the main urban areas. Thirteen (31.0%) patients had a history of contact with an individual with pulmonary TB (Table 1).

The most common symptoms of culture-confirmed children patients with TBM included fever (90.5%), headache (71.4%), neck stiffness (83.3%), vomiting (52.4%), cough (45.2%), disturbance of consciousness (33.3%) and varying degrees of convulsions, weight loss and night sweats (Table 1). Symptomatic resolution occurred in 35/42 (83.3%) patients following hospitalisation with an average length of stay (LOS) of 21 days. One patient (2.4%) died and 6/42 (14.3%) developed long term sequelae. During hospitalization, patients showed varying degrees of anti-tuberculosis drug-induced hyperuricemia (23.8%) and hepatotoxicity (14.3%) (Table 1).

**Laboratory and imaging findings**
Chest X-rays changes were observed in all patients, and 18/42 (42.9%) patients had clinical evidence of extra-pulmonary and extracranial TB disease involving sites such as the cervical lymph nodes, pericardium, and peritoneum. Brain imaging showed varying degrees of basal meningeal enhancement (28.6%) and cerebral edema/Hydrocephalus (16.7%). In addition, thirty 30/42 (71.4%) patients had high CSF pressure >200mmH2O (Table 1).

Laboratory testing revealed that 100.0%, 88.1%, 73.8% and 61.9% of patients had CSF total leucocyte count of >20 cells/μL, CSF sugar levels < 2.2 mmol/L, proteins >1.0 mg/dl and abnormal erythrocyte sedimentation rate (ESR), respectively. According to the results from 42 children patients with TBM, 17 (40.5%) had anemia, while Lactate dehydrogenase (54.8%), Hydroxybutyrate dehydrogenase (64.3%), C-Reactive protein (60.0%) and blood lactates acid (28.6%) were present to different degrees (Table 2).

**Drug resistance**

CSF specimens from all 42 cases were culture-positive for *Mycobacterium tuberculosis*. DST was performed on all 42 culture positive specimens; resistance to any ATD was demonstrated in 13 / 42 (31%) isolates with 12 and 3 instances of first-line drug resistance and second-line drug resistance, respectively. In addition, two (4.8%) and 1 (2.4%) isolates were identified as MDR-TB and XDR-TB respectively, and the resistance to single ATD (from high to low) i.e., isoniazid (high-level resistance > 1.6 μg/ml) 10/42(23.8%), streptomycin (high-level resistance > 8.0 μg/ml) 4/42(9.5%), rifampicin (high-level resistance > 8.0 μg/ml) 3/42 (7.5%) and ofloxacin (high-level resistance > 2.0 μg/ml), amikacin (high-level resistance > 4.0 μg/ml), protonamid (high-level resistance > 40.0 μg/ml), moxifloxacin (high-level resistance > 2.0 μg/ml), rifabutin (high-level resistance > 3.0 μg/ml) were 1 (2.4%), respectively (Table 3). No changes were observed in the drug resistance rate of MTB strain against eleven ATDs in 6 years: isoniazid (P = 0.44), streptomycin (P = 0.29), rifampicin (P = 0.38), ofloxacin (P = 0.38), moxifloxacin (P = 0.14), protonamid (P = 0.38), rifabutin (P = 0.38), amikacin (P = 0.38). Because the drug resistance rate in capreomycin, ethambutol, and levofloxacin was 0 for 6 years, it was not statistically significant.

**Geographical distribution**

The PHCCC is located in Chengdu city, the capital of Sichuan province. It is one of the oldest hospitals in the area and the authorized medical institution for treating TB in Chengdu city. The Geographical distribution figure revealed that most of the TBM cases in the current study were mainly from the Sichuan province, the southwest hinterland of the Chinese mainland. Meanwhile, most of the cases were mainly located in the ethnic areas of western Sichuan; there were also a few cases in the central and northern regions of Sichuan (Figure 1).

**Discussion**

China has the second-highest incidence of TB in the world. Located in the southwest hinterland of the Chinese mainland, Sichuan province is the gateway to the southwest of China. This area is a big multi-ethnic community with the second largest Tibetan region in China. Although the Chinese government has
strengthened TB control in minority areas over recent years achieving modest success, infantile TBM remains a neglected field [4-5]. WHO and numerous studies have reported that BCG vaccination can protect children from severe types of TB, such as TB meningitis and miliary TB [6-7]. Administration of BCG vaccination is already implemented in most parts of China. It has been estimated that 76% of infants receive BCG vaccination at birth in China [8]. However, in the current study, more than 80% of children with TBM were from ethnic minority areas in the southwest of China, with no history of BCG vaccination or BCG vaccination marks on the forearm. Only 2/42 (4.76%) of the patients with a history of BCG vaccination were Han Chinese from the main urban areas. Due to the remote geographical location and difficulties with transportation, there are many residents of ethnic minorities within Sichuan province who are unable to readily access medical services. Consequently, there is poor awareness of disease prevention and many residents do not go to the hospital to give birth. All of these obstruct the government's efforts to control TB, which is why BCG vaccination rates are low in these areas. Chinese government and WHO should also formulate corresponding TB control strategies for the population in these special areas.

Among forty-two children with a median age of 9 years, approximately 70% were between 5 and 14 years, and only 13 (31%) were under 5 years of age, which was somewhat different from some previous studies arguing that TBM mainly affects young children with the mean age ranging between 23 and 49 months [9-11]. This suggests that the BCG vaccine may have a certain protective effect not only on the incidence of TBM in early childhood but also in older children from different areas. It is possible that different regions, study population, and sample size may have a different age group structure.

In this study, there was no difference in distribution among male and female subjects. Among 42 patients, 1/42 (2.38%) patients died, while more than 83% patients successfully recovered during their stay at the hospital. There were no HIV-infected patients, while syphilis infection was found in one case. All the 42 cases had Chest X-rays suggestive of tuberculosis.

Following pulmonary infection with TB, children are more likely to develop disseminated disease and/or TBM due to their relatively lower immunity and development of initial non-specific symptoms that preclude early diagnosis. Fever (90.5%), headache (71.4%) and cough (45.2%) were the most common symptoms, while more severe symptoms like neck stiffness, vomiting, and disturbance of consciousness were present in 35/42 (83.3%), 22/42(52.4%), and 14/42 (33.3%), respectively. The occurrence of these symptoms was similar or higher to those observed in previous studies [12-15]. In addition, children with TBM during hospitalization showed varying degrees of anti-tuberculosis drug-induced hyperuricemia (23.8%) and hepatotoxicity (14.3%). These frequent adverse events associated with TB treatment ratio were higher in the current study compared to previous ones [5, 16].

Diagnosing TBM in children is difficult because of non-specific clinical features, insensitive laboratory tests and the low positive rate of CSF culture. Most of the reported cases of TBM lack the relevant bacteriological diagnostic basis [17-19], especially in children. In this study, the DST of TBM in children from southwest of China was high; ATD resistance and first-line drug resistance were 13 (31.0%) and 12
respective, which was similar to adult tuberculous meningitis in Chengdu area. Besides, the drug resistance rate of isoniazid, streptomycin and rifampicin ranked among the first three [2]. This was different from the low rates of isoniazid resistance observed in children in some other parts of China [20, 21] and similar to Shaanxi province of China [22]. In our study, children with TBM and MDR-TB accounted for two (4.8) cases; while there was one case with XDR. This incidence is relatively lower compared with other regions of China, which may be due to regional differences and the different group of cases in our study [20-22]. No significant change was observed in the drug resistance rate of MTB strain against eleven ATDs over 6 years.

**Conclusions**

We found that the children's TBM in southwest of China was mainly concentrated in the minority areas of western Sichuan, and that the vaccination rate of BCG vaccine was very low, while the drug resistance rate was high. To the best of our knowledge, this is the first study that reported the drug-resistance patterns of children with TBM in southwest China, thus providing basis for the prevention and treatment of tuberculous meningitis. The government can use these results to further strengthen the prevention and control of TB in southwest China, especially in ethnic minority areas.

**Abbreviations**

- **CSF**  Cerebrospinal fluid
- **PHCCC**  Public Health Clinical Center of Chengdu
- **NTM**  Nontuberculous Mycobacteria
- **MTB**  M.tuberculosis
- **DST**  Drug sensitivity testing
- **BCG**  Bacillus Calmette–Guérin
- **ATD**  Anti-tuberculosis drug
- **MDR-TB**  Multidrug-resistant tuberculosis
- **Pre-XDR**  Pre-Extensively Drug Resistant
- **XDR**  Extensively Drug Resistant
- **TB**  Tuberculosis
- **INH**  Isoniazid
RIF  Rifampicin
STR  Streptomycin
EMB  Ethambutol
OFX  Ofloxacin
LFX  Levofloxacin
MFX  Moxifloxacin
PTO  Prothionamide
RFB  Rifabutin
AMK  Amikacin
CM  Capreomycin
CLR  Clarithromycin
PNB  P-nitrobenzoic acid
TCH  Thiophene-2-carboxylic acid hydrazide
TB-DNA  Tuberculosis Deoxyribonucleic acid
EQA  External quality assessment
WHO  World Health Organization

Declarations

Acknowledgments

The authors thank Bin-Wu Ying, Chuan-Min Tao, Gui-Hui Wu, Xi Li, Ma Zhu, Yuan-Hong Xu, Jing Zhong, Jia Luo and Jie-Ying Li for their valuable help during the conduct of the study. The authors also thank Qing-Feng Li, the study coordinator, and all the other staff at the Clinical Laboratory for their help in the completion of this study.

Availability of data and material

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Funding
This study was supported by the Youth Innovation in Medical Research Subject in Sichuan Province of China [No. Q17020] (DMW, design of the study, analysis, interpretation of data and writing the manuscript) and the Chengdu Science and Technology Bureau [No. 2018JY0383] (QFL, date collection and supervision).

**Author contributions**

DMW conducted the primary analysis and wrote the manuscript. BWY, CMT, MZ, YHX, JL and YJL contributed reagents/materials/analysis tools. QFL, GHW, XL and JZ collected data. All authors read and approved the final manuscript.

**Notes**

**Ethics approval and consent to participate**

This study was approved by the Ethics Committee of PHCCC on [2017Y] 025. As this was a retrospective study and all patient information used in this study was routinely collected through the mandatory notification system, the requirement for informed consent was waived by the ethics committee.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare no conflicts of interest.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Contributor Information**

Dong-Mei Wang, Email: herringdong@126.com  
Qing-Feng Li, Email: 984797639@qq.com  
Ma Zhu, Email: 3060200865@qq.com  
Gui-Hui Wu, Email: 3119213561@qq.com  
Xi Li, Email: swpcc@126.com  
Yuan-Hong Xu, Email: 2595390796@qq.com
References

1. World Health Organization. Global tuberculosis report; 2019.

2. Wang DM, Li QF, Zhu M, Xu YH, Luo J, Li YJ, et al. Analysis of infection and drug-resistance in 6107 cases of extrapulmonary tuberculosis in Chengdu area. Chinese Journal of Tuberculosis and Respiratory Diseases. PMID:28810312. doi: 3760/cma.j.issn.1001-0939.2017.08.010

3. World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva: WHO Document Production Services; 2014.

4. Liping Pan, Fei Liu, Jinli Zhang, Xinting Yang, Shiqi Zheng, Jing Li, Hongyan Jia, Xiaoyou Chen, Mengqiu Gao, Zongde Zhang. Interferon-Gamma Release Assay Performance of Cerebrospinal Fluid and Peripheral Blood in Tuberculous Meningitis in China. Biomed Res Int. 2017; 2017: 8198505. Published online 2017 Feb 20. doi: 10.1155/2017/8198505.

5. Yu He, Chao Han, Kai-Feng Chang, Mao-Shui Wang, Tian-Ren Huang. Total delay in treatment among tuberculous meningitis patients in China: a retrospective cohort study. BMC Infect Dis. 2017; 17: 341. Published online 2017 May 12. doi: 10.1186/s12879-017-2447-0.

6. Yu Pang, Aihua Zhao, Chad Cohen, Wanli Kang, Jie Lu, Guozhi Wang, Yanlin Zhao, Suhua Zheng. Current status of new tuberculosis vaccine in children. Hum Vaccin Immunother. 2016 Apr; 12(4): 960–970. Published online 2016 Mar 22. doi: 10.1080/21645515.2015.1120393.

7. Acosta CD, Rusovich V, Harries AD, Ahmedov S, van den Boom M, Dara M. A new roadmap for childhood tuberculosis. Lancet Glob Health 2014; 2:e15-7; PMID:25104625; http://dx.doi.org/10.1016/S2214-109X(13)70153-0 [PubMed] [CrossRef].

8. National Technical Steering Group of the Epidemiological Sampling Survey for Tuberculosis. Report on fourth national epidemiological sampling survey of tuberculosis. Chin J Tuberc Respir Dis. 25, 3–7 (2002).

9. Van Well GT, Paes BF, Terwee CB, Springer P, Roord JJ, Donald PR, et al. Twenty Years of Pediatric Tuberculous Meningitis: A Retrospective Cohort Study in the Western Cape of South Africa. Pediatrics. 2009;123 (1): e1-8. doi:1542/peds.2008-1353. https://pediatrics.aappublications.org/content/123/1/e1.

10. Farinha NJ, Razali KA, Holzel H, Morgan G, Novelli VM. Tuberculosis of the central nervous system in children: a 20-year survey. J Infect. 2000; 41(1): 61–68.
11. Yaramiş A, Gurkan F, Elevli M, Söker M, Haspolat K, Kirbaş G, et al. Central nervous system tuberculosis in children: a review of 214 cases. Pediatrics. 1998; 102(5): E49. PMID: 9794979.

12. Anil V. Israni, Divya A. Dave, Anirban Mandal, Amitabh Singh, Puneet K. Sahi, Rashmi Ranjan Das, Arpita Shah. Tubercular meningitis in children: Clinical, pathological, and radiological profile and factors associated with mortality. J Neurosci Rural Pract. 2016 Jul-Sep; 7(3): 400–404. doi: 10.4103/0976-3147.181475.

13. Miftode EG, Dorneanu OS, Leca DA, Juganariu G, Teodor A, Humruzuache M. Tuberculous Meningitis in Children and Adults: A 10-Year Retrospective Comparative Analysis. PLoS One. 2015 Jul 17;10(7): e0133477. doi: 10.1371/journal.pone.0133477.

14. Nguyen Duc Bang, Maxine Caws, Thai Thanh Truc, Tran Ngoc Duong, Nguyen Huy Dung, Dang Thi Minh Ha, Guy E. Thwaites, Doortje Heemsker, Joel Tarning, Laura Merson, Pham Van Toi, Jeremy J. Farrar, Marcel Wolbers, Thomas Pouplin, Jeremy N. Day. Clinical presentations, diagnosis, mortality and prognostic markers of tuberculous meningitis in Vietnamese children: a prospective descriptive study. BMC Infect Dis. 2016; 16: 573. doi: 10.1186/s12879-016-1923-2.

15. Nabukeera-Barungi N, Wilmshurst J, Rudzani M, Nuttall J. Presentation and outcome of tuberculous meningitis among children: experiences from a tertiary children's hospital. Afr Health Sci 2014 Mar;14 (1): 143-9. PMID: 26060471 [Pubmed - MEDLINE].

16. Tae WY, Hyun OP, Ha NJ, Jun HY, Sung HK, Seong HM, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea A retrospective study. Medicine (Baltimore). 2017 Jul; 96(28): e7482. doi: 1097/MD.0000000000007482.

17. Anu Goenka, Prakash M. Jeena, Koleka Mlisana, Tom Solomon, Kevin Spicer, Rebecca Stephenson, Arpna Verma, Barnes Dhada, Michael J. Griffiths. Rapid Accurate Identification of Tuberculous Meningitis Among South African Children Using a Novel Clinical Decision Tool. Pediatr Infect Dis J. 2018 Mar; 37(3): 229–234. doi: 10.1097/INF.0000000000001726.

18. Ursula K Rohlwink, Kirsty Donald, Bronwyn Gavine, Llewellyn Padayachy, Jo M Wilmshurst, Graham A Fieggen, Anthony A Figaji. Clinical characteristics and neurodevelopmental outcomes of children with tuberculous meningitis and hydrocephalus. Dev Med Child Neurol. 2016 May; 58(5): 461–468. doi: 10.1111/dmcn.13054.

19. Ali Güneş, Ünal Uluca, Fesih Aktar, Çapan Konca, Velat Şen, Aydin Ece, Salih Hoşoğlu, Mehmet Ali Taş, Fuat Gürkan. Clinical, radiological and laboratory findings in 185 children with tuberculous meningitis at a single centre and relationship with the stage of the disease. Ital J Pediatr. 2015; 41: 75. doi: 10.1186/s13052-015-0186-

20. Jiao WW, Liu ZG, Han R, Zhao XQ, Dong F, Dong HY, et al. Prevalence of drug resistant Mycobacterium tuberculosis among children in China. Tuberculosis (Edinb). 2015 May;95(3):315-20. doi: 10.1016/j.tube.2015.02.041.

21. Guo Q, Pan Y, Yang Z, Liu R, Xing L, Peng Z, et al. Epidemiology and Clinical Characteristics of Pediatric Drug-Resistant Tuberculosis in Chongqing, China. PLoS One. 2016 Mar 9;11(3):e0151303.
22. Wang T, Feng GD, Pang Y, Liu JY, Zhou Y, Yang YN, et al. High rate of drug resistance among tuberculous meningitis cases in Shaanxi province, China. Sci Rep. 2016 May 4;6:25251. doi: 10.1038/srep25251.

23. World Health Organization. Worldwide prevalence of anaemia. Global Database on Anaemia; 2008.

Tables
Table 1. Demographic profile and clinical features of culture-confirmed children TBM in Southwest China, 2013-2018 (n = 42)

| Variable                                      | Total n = 42 (%) |
|-----------------------------------------------|------------------|
| Mean age; months (range)                      | 93; 5-168⁶       |
| <1 years                                      | 5 (11.9)         |
| 1-5 years                                     | 8 (19.0)         |
| 5-14 years                                    | 29 (69.0)        |
| Female                                        | 21 (50.0)        |
| BCG vaccination                               | 2 (4.8)          |
| Chinese Ethnic minorities                     |                  |
| Han                                           | 7 (16.7)         |
| Tibetan                                       | 27 (64.3)        |
| Yi                                            | 6 (14.3)         |
| Qiang                                         | 1 (2.4)          |
| History & Clinical Findings                   |                  |
| Temperature above 37.5°C                      | 38 (90.5)        |
| Headache                                      | 30 (71.4)        |
| Convulsions                                   | 4 (9.5)          |
| Disturbance of consciousness                  | 14 (33.3)        |
| Cough                                         | 19 (45.2)        |
| Vomiting                                      | 22 (52.4)        |
| Weight loss                                   | 6 (14.3)         |
| Night sweats                                  | 3 (7.1)          |
| Neck stiffness                                | 35 (83.3)        |
| CSF pressure >200 mmH2O                       | 30 (71.4)        |
| **Recent close contact with an infectious TB case** | 13 (31.0)     |
| Imaging                                       |                  |
| Chest X-ray suggestive of TB                  | 42 (100.0)       |
| Basal meningeal enhancement                  | 12 (28.6)        |
| Cerebral oedema/Hydrocephalus                 | 7 (16.7)         |
| Outcome                                       |                  |
| Recovery                                      | 35 (83.3)        |
| Sequelae                                      | 6 (14.3)         |
| Death before hospital discharge               | 1 (2.38)         |
| Drug-induced Uric acid UA (> 430 μmol / L)    | 10 (23.8)        |
| ATD-induced hepatotoxicity⁵                   | 6 (14.3)         |

b History of recent (within past year) close contact with an individual with pulmonary TB.

c The ATD induced hepatotoxicity is defined as ALT ≥ 3ULN.
### Table 2. Laboratory findings of culture-confirmed children TBM in Southwest China, 2013-2018 (n = 42)

| Variable | Total n = 42 (%) |
|----------|-----------------|
| **Cerebrospinal fluid results** | |
| Total leukocyte count / µl; median (range) | 381-20-1300 |
| 10 to 99 | 8 (19.0) |
| 100 to 399 | 19 (45.2) |
| > 400 | 15 (35.7) |
| Lymphocytes (cells×106 / L) > 50% | 32 (76.2) |
| 25 to 50 | 7 (16.7) |
| 51 to 75 | 17 (40.5) |
| > 75 | 15 (35.7) |
| Protein >1.0 mg/dl | 31 (73.8) |
| Glucose < 2.2 mmol/L | 37 (88.1) |
| Chloride < 110 mmol/L | 20 (47.6) |

**Blood results**

| Variable | Total n = 42 (%) |
|----------|-----------------|
| ESR (Female > 20, male > 15 mm / hour) | 26 (61.9) |
| Lactate dehydrogenase ( > 225 U/L) | 23 (54.8) |
| Hydroxybutyrate dehydrogenase ( > 182 U/L) | 27 (64.3) |
| Anemia* | 17 (40.5) |
| C-Reactive protein ( > 6 mg / L ) | 25 (60.0) |
| Blood lactates acid ( > 2.2 mmol/L) | 12 (28.6) |

ESR erythrocyte sedimentation rate; *0.5-4.99 yrs Hemoglobin < 110g/L, 5-11.99 yrs Hemoglobin < 115g/L, 12-14.99 yrs Hemoglobin < 120g/L[23].
| Individual drug | No.(%) of isolates with resistant to (n = 42) |
|-----------------|--------------------------------------------|
| Any drug resistance* | 13 (31.0) |
| Any first-line drug resistance | 12 (28.6) |
| Any second-line drug resistance | 3 (7.1) |
| STR | 4 (9.5) |
| INH | 10 (23.8) |
| RIF | 3 (7.1) |
| EMB | 0 (0.0) |
| OFX | 1 (2.4) |
| LFX | 0 (0.0) |
| AMK | 1 (2.4) |
| CM | 0 (0.0) |
| PTO | 1(2.4) |
| MFX | 1 (2.4) |
| RFB | 1 (2.4) |
| MDR (INH+RIF) | 2 (4.8) |
| pre-XDR | 0 (0.0) |
| XDR | 1 (2.4) |
| INH+STR | 2 (4.8) |
| INH+RIF+STR | 1 (2.4) |
| INH+RIF+EMB | 0 (0.0) |
| RIF+STR+EMB | 0 (0.0) |
| INH+RIF+STR+EMB | 0 (0.0) |

TBM, tuberculosis meningitis; DST, drug sensitivity testing; INH, isoniazid; STR, streptomycin; RIF, rifampicin; EMB, ethambutol; OFX, Ofloxacin; LFX, Levofloxacin; MFX, Moxifloxacin; PTO, Protionamid; RFB, Rifabutin; AMK, Amikacin; CM, Capreomycin; MDR-TB, multidrug-resistant tuberculosis; XDR, extensively drug-resistant tuberculosis; *: Resistant to at least one drug.

Figures
Figure 1

The geographical distribution of the People's Republic of China, the insert reports a magnification of the southwest of China where 42 study cases are present. Site locations (triangle) are red coloured according to the children TBM prevalence cases. Note: The designations employed and the presentation of the material on this map do not imply the expression of any opinion whatsoever on the part of Research Square concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. This map has been provided by the authors.